Esomac 40mg Tablet

Esomac 40mg Tablet is proton pump inhibitor prescribed by the doctor that is mainly used to reduce stomach acid production for treating conditions like gastroesophageal reflux disease (GERD), peptic ulcers, erosive esophagitis, and Zollinger-Ellison syndrome.Esomac 40mg Tablet contains Esomeprazole that prevents both basal and stimulated acid production, resulting in long-lasting anti secretory effects that continue for more than 24 hours until new pumps are produced.

Esomac 40mg Tablet is a proton pump inhibitor. It has multiple side effects that range from common to extreme. Consult your doctor, if symptoms persists for longer period of time or if you experience any of the serious side effects.
● Vomiting
● Nausea
● Fatigue
● Diarrhea
● Decreased Appetite
● Abdominal Pain
● Severe Allergic Reaction
● Low Magnesium Content
● Gastric Bleeding

Esomac 40mg Tablet is taken orally once a day on empty stomach. This is the usual starting dosage for adults but can vary later based on the type of disease and its progression. Tablets should be consumed whole as it is without breaking, chewing or biting to maintain their efficacy. For exact dosage, contact your doctor. Don't miss the dosage and remain consistent about medication.

Esomac 40mg Tablet contains Esomeprazole inhibits the last stage of acid secretion into the stomach lumen permanently by covalently binding to sulfhydryl groups on the H+/K+-ATPase enzyme (proton pump) at the secretory surface in the acidic environment of gastric parietal cells. Regardless of the stimulus (such as histamine or gastrin), this prevents both basal and stimulated acid production, resulting in long-lasting anti secretory effects that continue for more than 24 hours until new pumps are produced.

• Scott, L. J., Dunn, C. J., Mallarkey, G., & Sharpe, M. (2002). Esomeprazole: a review of its use in the management of acid-related disorders. Drugs, 62(10), 1503-1538.
• Johnson, T. J., & Hedge, D. D. (2002). Esomeprazole: a clinical review. American journal of health-system pharmacy, 59(14), 1333-1339.
• Lindberg, P., Keeling, D., Fryklund, J., Andersson, T., Lundborg, P., & Carlsson, E. (2003). Esomeprazole—enhanced bio‐availability, specificity for the proton pump and inhibition of acid secretion. Alimentary pharmacology & therapeutics, 17(4), 481-488.
• Pipaliya, N., Solanke, D., Rathi, C., Patel, R., Ingle, M., & Sawant, P. (2016). Esomeprazole induced galactorrhea: a novel side effect. Clinical journal of gastroenterology, 9(1), 13-16.